Sign In
Buy VNDA
$6.09
-0.0400 (-0.653%)
At Close: Jun 03, 2026
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
08:00am, Monday, 07'th Apr 2025
WASHINGTON , April 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San
WASHINGTON , March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (
WASHINGTON , Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Cha
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript
10:29pm, Thursday, 13'th Feb 2025
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, Presid
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
06:21pm, Thursday, 13'th Feb 2025
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Thursday, 13'th Feb 2025
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total revenues of $198.8 million, +3% com
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
04:30pm, Wednesday, 05'th Feb 2025
Conference Call and Webcast to Follow WASHINGTON , Feb. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and ful
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys to r
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
07:00am, Monday, 27'th Jan 2025
Highlights faulty FDA review WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Gastroparesis
Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
04:17pm, Wednesday, 08'th Jan 2025
WASHINGTON , Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. As previously reported, Vanda has sou
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
01:11pm, Monday, 06'th Jan 2025
Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.
Nvidia stock inflows reach $30B: Vanda Research
01:30pm, Friday, 27'th Dec 2024
Retail investors flocked to Nvidia (NVDA) in 2024. According to Vanda Research, the chip giant saw nearly $30 billion in inflows during the year.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
08:50am, Tuesday, 24'th Dec 2024
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity
01:26pm, Friday, 20'th Dec 2024
Vanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt and PONVORY distribution. I'm interested in buying the stock prior to FY 2024 resul
WASHINGTON , Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-184
